Courtney Fletcher, Pharm.D.
Every child who receives HIV treatment today has benefited from the drug research of Courtney Fletcher, Pharm.D.
Dr. Fletcher’s pharmacologic efforts led the Food and Drug Administration to approve two major HIV/AIDS drug inhibitors in children: atazanavir and efavirenz.
Years ago, HIV/AIDS research extended a patient’s life about six months on average, Dr. Fletcher said. "Now we think of HIV as a manageable chronic disease,” he said.
In 2008, Dr. Fletcher brought more than $9.5 million in research to UNMC, when he became dean of the College of Pharmacy. Already, the Greybull, Wyo., native has transformed the college into a research powerhouse. The College of Pharmacy ranks in the top 10 of pharmacy schools in terms of per faculty member research funding.
Much of Dr. Fletcher’s early research work was done at the University of Minnesota on cytomegalovirus (CMV). His focus turned to HIV/AIDS when AIDS patients were diagnosed with CMV infection, potentially life-threatening for patients who have compromised immune systems. Dr. Fletcher took his research to the University of Colorado Health Sciences Center in Denver before joining UNMC.
Dr. Fletcher is a past member of the National Institutes of Health’s AIDS Discovery and Development of Therapeutics Study Section and the U.S. Food and Drug Administration's Antiviral Drug Advisory Committee. He is a member of the U.S. Department of Health and Human Services (DHHS) Panel on Clinical Practices for the Treatment of HIV Infection.